<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682172</url>
  </required_header>
  <id_info>
    <org_study_id>H-17037571</org_study_id>
    <nct_id>NCT03682172</nct_id>
  </id_info>
  <brief_title>Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects</brief_title>
  <official_title>Effect of Glucagon-like Peptide 2 on Postprandial Gallbladder Motility in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effect of the incretin hormone glucagon-like peptide 2 (GLP-2)
      on postprandial gallbladder motility in young, healthy, male subjects.

      The study is double-blinded, randomized and placebo controlled. 15 subjects will be included.
      On three separate study days (A, B, C) the subjects will receive an four hour intravenous
      infusion with either saline (placebo), GLP-2 at a rate of 1 pmol/kg/min or GLP-2 at a rate of
      10 pmol/kg/min 30 minutes after the infusion start the subject will receive a liquid meal
      which will stimulate gallbladder contraction.

      The gallbladder volume will be determined by frequent ultrasonic scans, and blood samples
      will be drawn on fixed times through out the study day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design The primary endpoint is the incremental Area Under the Curve (iAUC) of the
      gallbladder Ejection Fraction % (EF) at time 0-210 minutes. Gallbladder volume will be
      measured during a four hour intravenous GLP-2 infusion at two different concentrations (1
      pmol/kg body weight/min and 10pmol/kg body weight/min), respectively, compared to placebo
      after ingestion of a liquid meal in healthy, young, male subjects. The gallbladder volume
      will be quantified by multiple ultrasonography scans at fixed times during the experimental
      study days.

      Gallbladder ejection fraction (EF%) will be calculated as following:

      Gallbladder EF = (gallbladder volume, baseline - gallbladder volume, at a given time t) /
      gallbladder volume, baseline * 100. The gallbladder volume is determined by bedside
      ultrasonography.

      15 healthy male subjects will be included according to the inclusion and exclusion criteria
      listed below.

      Inclusion criteria:

      Sex: Male Ethnicity: Caucasian Age: 18-35 years BMI: 18.5-24.9 Fasting plasma glucose: 6
      mmol/l or below Glycated haemoglobin (HbA1c): 42 mmol/mol or below Haemoglobin: 8.3-10.5
      mmol/l

      Exclusion criteria:

      First-degree relatives with type 1 or type 2 diabetes Nephropathy (serum creatinin &gt; 130
      micromole/l) Liver disease Active or recent malignant disease

      A subject will participate in three study days (day A, B and C) with a minimum of 48 hours
      between each day. The three days will differ in regards to the intravenous infusion:

      Study day A (placebo):

      Subjects arrive at the laboratory after an overnight fast (10h). Two cannulas will then be
      inserted in the cubital veins (one in each arm) for collection of blood samples and
      administration of saline (placebo), respectively. The forearm from which blood samples are
      drawn will be wrapped in a heating pad throughout the experiment. The participant must rest
      30 minutes before start of the experimental procedures.

      At time -30 min, saline infusion (placebo) will be started.

      At time 0 min the participant will ingest a mixed liquid meal (200 ml, 1260 kJ) mixed with
      paracetamol (1,500 mg) dissolved in 100 ml of water.

      At time -60, -30, -15, 0, 10, 30, 50, 70, 90, 120, 150, 180 and 210 min gallbladder height,
      width and length will be determined by ultrasound (LOGIQ E9, GE Healthcare, Waukesha, WI,
      USA) for evaluation of gallbladder volume (calculated by the ellipsoid method).

      Blood samples will be collected at time -45, -40, -35, -20, -5, 20, 40, 60, 80, 100, 140 and
      200 min for the analysis of plasma/serum concentrations of glucose, GLP-1, GLP-2, GIP,
      glucagon, OXM, PYY, ghrelin, gastrin, CCK, FGF-19, insulin, C-peptide, bile acids, free fatty
      acids, paracetamol and triglycerides.

      Experimental Day B (GLP-2 (1 pmol/kg/min)) As experimental Day A, but with infusion of GLP-2
      (1 pmol/kg/min) instead of the saline infusion.

      Experimental Day C (GLP-2 (10 pmol/kg/min)) As experimental Day A, but with infusion of GLP-2
      (10 pmol/kg/min) instead of the saline infusion.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>It is a blinded, randomized, placebo controlled study where 15 participants receive three different 4 hour intravenous infusions of either saline (placebo), low GLP-2 (at a rate of 1pmol/kg/min) or high GLP-2 (at a rate of 10pmol/kg/min) on three different study days.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gallbladder ejection fraction (EF%)</measure>
    <time_frame>0-210 minutes</time_frame>
    <description>Incremental Area Under the Curve (iAUC) for gallbladder ejection fraction (EF%) at time 0-210 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>-30-200 minutes</time_frame>
    <description>Incremental Area Under the Curve (iAUC) (-30;200min) of glucagon plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>0-200 minutes</time_frame>
    <description>Gastric emptying will be determined by the by paracetamol curve following ingestion of the meal (mixed with 1500 mg paracetamol).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum gallbladder EF%</measure>
    <time_frame>0-210 minutes</time_frame>
    <description>Time to reach maximum gallbladder ejection fraction.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Effect of Glucagon-like Peptide 2 on Gallbladder Motility</condition>
  <arm_group>
    <arm_group_label>GLP-2 (10pmol/kg/min)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10pmol/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-2 (1pmol/kg/min)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single four hour intravenous infusion with saline water (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-2 (1pmol/kg/min)</intervention_name>
    <description>Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min</description>
    <arm_group_label>GLP-2 (1pmol/kg/min)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-2 (10pmol/kg/min)</intervention_name>
    <description>Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min</description>
    <arm_group_label>GLP-2 (10pmol/kg/min)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Four hour intravenous infusion with saline water</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian ethnicity

          -  Male

          -  Age: 18-35 years

          -  BMI: 18,5-24,9

          -  Fasting plasma glucose ≤ 6 mmol/l

          -  Glycated haemoglobin (HbA1c) ≤ 42 mmol/mol

          -  Normal haemoglobin (8,3-10,5 mmol/l)

          -  Informed and written consent

        Exclusion Criteria:

          -  First-degree relatives with type 1 or type 2 diabetes

          -  Nephropathy (se-creatinin &gt; 130 μM and/or albuminuria)

          -  Liver disease (alanintransaminase (ALAT) or aspartattransaminase (ASAT) &gt; 2 × upper
             normal limit)

          -  Active or recent malignant disease

          -  Treatment with medicine that cannot be paused for 1 week

          -  Any treatment or condition requiring acute or sub-acute medical or surgical
             intervention

          -  Any condition considered incompatible with participation by the investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Hellerup</city>
        <state>Region Hovedstaden</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gallbladder Motility</keyword>
  <keyword>Gallbladder Emptying</keyword>
  <keyword>Glucagon-Like Peptide 2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

